Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Accentia Biopharmaceuticals brings in $8.7mm privately

Executive Summary

Accentia Biopharmaceuticals (develops already-approved drugs for additional conditions) has raised $8.7mm by selling new and existing institutional investors preferred stock that converts into common shares at $2.67 apiece. The buyers also received short-term warrants (exercisable either 30 days after the company unveils the results of a Phase III rhinosinusitis study of SinuNase or during the 30 days after December 2, 2008) and six-year warrants to buy shares at $2.67 each. Rodman & Renshaw was the exclusive placement agent.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies